PRINCETON, N.J.--(BUSINESS WIRE)--
Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, was named to NJBIZ’s 2017 Best Places to Work in New Jersey list, as compiled and ranked by the Best Companies Group (BCG). Advaxis, which has grown from about 10 employees to more than 100 in the last three years, was among the honorees at an awards reception and ceremony on Wednesday, April 26.
Companies on this prestigious list stand out for prioritizing their employees’ professional growth and quality of life, as judged on a critical review of policies, practices, employee demographics and an anonymous employee survey. Advaxis ranked 34th of the top 100 employers across the state.
BCG evaluates each nominated company’s policies, practices and demographics. As part of the nomination and review process, BCG confidentially surveys employees about how they view workplace benefits and policies, professional growth and well-being and their overall experience at the company. To qualify for consideration, more than 70 percent of employees must complete the survey. The initial evaluation and employee survey scores were then combined to determine the top companies and their rankings.
“With so many prestigious companies, institutions and organizations throughout the state, we are honored to be named among the Best Places to Work in New Jersey,” said Sara M. Bonstein, Executive Vice President and Chief Financial Officer of Advaxis. “Advaxis has been able to grow thanks to our talented workforce, and our continued success is a result of our employees’ commitment to providing much needed therapeutic treatments for hard-to-treat cancers. Fostering a positive and engaging environment that promotes recognition, growth opportunities and great benefits has always been a priority for Advaxis, and we thank our staff, BCG and NJBIZ for this award.”
The awards reception and ceremony hosted by NJBIZ was held at iPlay America’s Event Center in Freehold, NJ. For more information on the 2017 Best Places to Work in New Jersey program, please visit www.BestPlacestoWorkinNJ.com. To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, and YouTube.
About Advaxis, Inc.
Located in Princeton, N.J., Advaxis, Inc. is a biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis' lead Lm Technology immunotherapy, axalimogene filolisbac, targets HPV-associated cancers and is in clinical trials for three potential indications: Phase 3 in invasive cervical cancer, Phase 2 in head and neck cancer, and Phase 2 in anal cancer. The FDA has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings, as well as Fast Track designation for adjuvant therapy for HRLACC patients and a SPA for the Phase 3 AIM2CERV trial in HRLACC patients. Axalimogene filolisbac has also been classified as an advanced therapy medicinal product for the treatment of cervical cancer by the EMA’s CAT. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development. In addition, Advaxis and Amgen are developing ADXS-NEO, a preclinical investigational cancer immunotherapy treatment designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor, with plans to enter the clinic in 2017.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis’ proprietary immunotherapy, axalimogene filolisbac. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis’ SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2016, which is available at http://www.sec.gov.
Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law.
You are cautioned not to place undue reliance on any forward-looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170427005814/en/
